BROMOCRIPTINE IN THE TREATMENT OF ADVANCED PARKINSONISM
- 29 January 2009
- journal article
- research article
- Published by Hindawi Limited in Acta Neurologica Scandinavica
- Vol. 56 (3) , 274-276
- https://doi.org/10.1111/j.1600-0404.1977.tb01434.x
Abstract
The dopaminergic agonist bromocriptine in doses of 2.5-40 mg was compared with placebo in a double-blind cross-over study (12 + 12 wk) in 11 Parkinson patients. A bothering dyskinesia appeared after prolonged L-dopa treatment, limiting the L-dopa dose to a level where Parkinson symptoms were still present to an unsatisfactory degree. Based on changes in rating scales and the patients'' preference, bromocriptine was significantly superior to placebo. Dyskinesia, occurring during bromocriptine treatment in 9 of 11 patients, disappeared within the period of study in 6 patients after dose reduction, without changes in Parkinson disability scores, to placebo level. Bromocriptine seemed to be of value in cases where the balance between minimal dyskinesia and Parkinson symptoms was impossible to obtain with L-dopa treatment alone.This publication has 2 references indexed in Scilit:
- EFFECT of CB 154 (2-BROMO-ALPHA-ERGOCRYPTINE) ON PARALYSIS AGITANS COMPARED WITH MADOPAR IN A DOUBLE-BLIND, CROSS-OVER TRIALActa Neurologica Scandinavica, 1976
- IDIOPATHIC PARKINSONISM TREATED WITH BROMOCREPTINEThe Lancet, 1975